Cybin D/B/A Helus Pharma HELP
9.03 USD +0.23 (+2.61%)
At closeNov 3, 2026, 5:27 PM EST
9.21 +0.18 +1.99%
After hours · Nov 3, 5:27 PM ET
8.94 Day range 9.57
3.76 52-week range 15.15
- YTD
- +10.39%
- 1 year
- +34.18%
- Market cap
- 659.82M
- EPS (ttm)
- -4.15
- Shares out
- 73.06M
- Forward P/E
- -7.55
- YTD return
- +10.39%
- 1-year return
- +34.18%
- Volume
- 1.23M
- Avg volume
- 1.75M
- Open
- 9.11
- Previous close
- 8.80
- Day's range
- 8.94 – 9.57
- 52-week range
- 3.76 – 15.15
- Beta
- 0.63
- Analysts
- Strong Buy
- Price target
- 40.24 (+345.7%)
- Earnings date
- Nov 12, 2026
5D -1.33 (-13.23%)
Key statistics
- Enterprise value
- 831.64M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 3.51
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -82.43M
- Total cash
- 166.36M
- Total debt
- 0
- Return on equity
- -86.94%
- Short % of float
- 0.00%
- 50-day average
- 10.70
- 200-day average
- 7.11
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 40.24 +345.7% upside
Now 9.03
- Target (low)
- 15.08
- Target (mean)
- 40.24
- Target (high)
- 69.16
Ratings (0m) 11 11 buy · 0 hold · 0 sell
- Strong buy1
- Buy10
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 12, 2026
Expected Nov 12, 2026. Consensus EPS estimate -0.9448.
Financials — quick view
HELP Revenue — quarterly 0
HELP Net income — quarterly -47.82M
HELP EPS — quarterly -0.91
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | -0.67 | — | — | — |
| Aug 14, 2026 | Jun 30, 2026 | -0.83607 | -0.91 | -0.07 | -8.84% |
| Jun 30, 2026 | Mar 31, 2026 | -1.04 | -0.95583 | +0.08 | +8.09% |
| Feb 13, 2026 | Dec 31, 2025 | -0.53 | -0.99243 | -0.46 | -87.25% |
| Nov 13, 2025 | Sep 30, 2025 | -0.74 | -1.39 | -0.65 | -87.84% |
| Aug 13, 2025 | Jun 30, 2025 | -0.95779 | -1.10 | -0.14 | -14.72% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 18, 2026 | Barclays | init | — | Overweight |
| Aug 20, 2026 | TD Cowen | main | Buy | Buy |
| Jul 27, 2026 | Wells Fargo | init | — | Overweight |
| Jul 9, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 1, 2026 | Canaccord Genuity | main | Buy | Buy |
| Apr 13, 2026 | TD Cowen | init | — | Buy |
About Cybin D/B/A Helus Pharma
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- helus.com
News
Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference 
Helus Pharma Appoints Mark Lawson As Board Chair, Effective Immediately 
Helus Pharma Announces Co-Founders' Transition from Executive Leadership as Company Advances Toward Next Stage of Development 
Wells Fargo Maintains Overweight on Helus Pharma, Raises Price Target to $22 
Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026 
Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors 
Helus Pharma: A Buy Ahead Of The HLP003 Phase 3 Readout 
Helus Pharma to Host Investor Presentation on October 21, 2026 
Helus Pharma Announces Completion of Legal Name Change 
Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression
Your note
Sign in to keep a note on HELP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Bartlone (Aaron Frank) | Senior Officer of Issuer | Acquisition or disposition in the public market | Sep 1, 2026 | 225,154 |
| Cavers (Gregory Joseph) | Senior Officer of Issuer | Acquisition or disposition in the public market | Sep 1, 2026 | 125,937 |
| Fahel (Gabriel) | Senior Officer of Issuer | Acquisition or disposition in the public market | Sep 14, 2026 | 102,958 |
| Froese (Grant B.) | Director of Issuer | Exercise of rights | Aug 31, 2026 | 0 |
| Glavine (Paul) | Director of Issuer | Acquisition or disposition in the public market | Sep 7, 2026 | 4,247,694 |
| Hoskins (Eric William) | Director of Issuer | Exercise of rights | Aug 31, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Venrock Adviser, LLC | 4.89% | 3,851,654 | 52.81M | Jun 29, 2026 |
| Orbimed Advisors LLC. | 4.16% | 3,271,400 | 44.85M | Jun 29, 2026 |
| Adage Capital Partners GP L.L.C. | 3.89% | 3,060,000 | 41.95M | Jun 29, 2026 |
| Millennium Management Llc | 3.34% | 2,632,156 | 36.09M | Jun 29, 2026 |
| Rosalind Advisors, Inc. | 2.49% | 1,956,814 | 26.83M | Jun 29, 2026 |
| Sphera Funds Management Ltd. | 2.06% | 1,620,753 | 22.22M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 0.47% | 367,432 | 5.04M | Aug 30, 2026 |
| ROYCE FUND-Royce Smaller-Companies Growth Fund | 0.29% | 232,000 | 3.18M | Jun 29, 2026 |
| Invesco Exch-Trd Fd. TRT II-Invesco NASDAQ Future Gen 200 ETF | 0.03% | 24,576 | 336.94K | Jul 30, 2026 |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.02% | 15,991 | 219.24K | Jul 30, 2026 |
| TIFF INVESTMENT PROGRAM-TIFF Multi-Asset Fund | 0.00% | 1,804 | 24.73K | Jun 29, 2026 |